Biocon Biologics has one of the deepest portfolios of biosimilars in the industry, including several molecules in immunology. Two molecules, in-licensed from partners, have been commercialized.

Adalimumab*

Approved in 50+ countries, including the U.S., EU countries, Japan, Canada, Australia, NZ & several EM countries

Commercialized in EU countries, Japan, Canada

Etanercept

Approved in ~40 countries, including EU countries, Australia and several EM countries

Commercialized in EU countries

Ustekinumab